Ontruzant trastuzumab-dttb

Before prescribing ONTRUZANT, please read the accompanying
Prescribing Information, including the Boxed Warning about cardiomyopathy,
infusion reactions (pulmonary toxicity), and embryo-fetal toxicity.


THE MERCK ACCESS PROGRAM

CAN HELP ANSWER QUESTIONS ABOUT

  • Benefit investigations
  • Billing and coding
  • Co-pay assistance for eligible patients
  • The prior authorization and appeals process
  • Referral to the Merck Patient Assistance Program for eligibility determination (provided through the Merck Patient Assistance Program, Inc)
  • Product distribution
  • Merck’s Response to Coronavirus (COVID-19)

    During this unprecedented time, Merck is committed to ensuring our medicines reach our patients and customers. If you have concerns that your patient may have lost their insurance coverage due to the COVID-19 pandemic or may not be able to afford their medication, we encourage you to call The Merck Access Program.

    For more details about Merck’s response to coronavirus, visit our COVID-19 information page.

  • Sign up With the Electronic Enrollment Form With E-Signature

  •  
  •  


 WELCOME TO

THE MERCK ACCESS PROGRAM

ARE YOU A US HEALTH CARE PROFESSIONAL?

Please choose